HAMILTON, ON, July 31,
2024 /CNW/ - Insight Medbotics, a medical device
company combining the accuracy of MRI with the precision of
robotics, is pleased to announce two appointments to the company's
Clinical Advisory Board:
- Mark Emberton, MD, of University College London, in
London, UK
- Jeffrey Bassett, MD, MPH, of Hoag Hospital in Orange
County, USA
Insight Medbotics develops MRI-guided robotics to advance its
technology to procedures where accuracy and precision matter most
to patients, physicians and hospitals. The IGAR system has been
clinically demonstrated in breast cancer patients and is the
world's first and only FDA-cleared, MRI-compatible robot.
With a FDA 510(k) clearance in breast biopsy, Insight Medbotics
envisions development in other biopsies, therapy delivery, and
device placement. Prostate cancer, which still relies on imprecise
biopsy methodologies and radical whole gland treatment, is the next
patient care area where the IGAR robotics system could play a
leading role in delivering higher efficacy, better economics, and
an improved patient experience.
"I am excited to welcome Dr. Emberton and Dr. Bassett to our
clinical advisory team," says Fazila
Seker, CEO of Insight Medbotics and member of the Board of
Directors, "They are each visionaries in shaping a better future
for prostate cancer management and improving the patient
experience. Their combined clinical expertise in prostate cancer,
urologic care, clinical trials, and adoption of new technologies
like robotic surgery and focal therapy will be invaluable as
Insight Medbotics executes its commercialization strategy."
Dr. Mark Emberton is
professor of Interventional Oncology within the Division of Surgery
and Dean of the Faculty of Medical Science at University College
London in London, UK. He is
clinically active and holds the position of Honorary Consultant
Urologist at University College London Hospitals NHS Trust where he
works as a specialist in prostate cancer.
Through his academic work, Dr. Emberton has developed novel
diagnostic strategies and new therapies for men with prostate
cancer. His research resulted in the transformation of both the
diagnostic and therapeutic pathways, which have been incorporated
into international guidelines. He has published over 500 peer
review papers and holds a large grant portfolio.
"Robotics holds considerable promise to minimize the number of
hospital events and interventions for individuals who are at risk
of prostate cancer. Consolidating multiple procedures into a single
setting through robotic sampling and AI-guided procedures may also
reduce repetitive testing while supporting overall cost-effective
approaches that improve patient outcomes."
~ Mark Emberton, MD, member of the Clinical
Advisory Board, Insight Medbotics
Dr. Jeffrey
Bassett is the Ben and Carmela Du Endowed Chair of
Urologic Oncology at Hoag Memorial Hospital Presbyterian in
Newport Beach, CA, USA. The
hospital ranks among California's
top 10 hospitals, delivering community access to the most advanced
care. Dr. Bassett specializes in minimally invasive robotic surgery
for cancers of prostate, bladder, kidney, and testes. His interests
include emerging focal therapies, circulating and urinary
biomarkers, and molecular imaging. Improving patient outcomes and
the care experience remains his passion.
"As a surgeon, I'm always seeking new techniques to advance
patient care. Urologists and urologic oncologists have embraced
MRI-guided biopsy as the standard of care and are no longer
intimidated by MRI. In the near term, it may be possible to combine
prostate imaging and biopsy into one step. Robotics can potentially
streamline patient care this way and help make MRI accessible for
precision treatment strategies."
~ Jeffrey Bassett, MD, member
of the Clinical Advisory Board, Insight Medbotics
Insight Medbotics was created as a start-up company by the
Centre for Surgical Invention and Innovation (CSii), and MDA.
About Insight Medbotics
Insight Medbotics is
developing MRI-guided robotics to advance its technology to
procedures where accuracy and precision matter most to patients,
physicians, and hospitals. IGAR, the company's MRI-compatible
robot, has been clinically demonstrated. As the only company to
receive a FDA 510(k) clearance for use of a robot inside an MRI,
Insight Medbotics is now advancing the technology to improve the
standard of care for prostate cancer. Learn more at
https://insightmedbotics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insight-medbotics-appoints-mark-emberton-md-jeffrey-bassett-md-mph-to-clinical-advisory-board-302210417.html
SOURCE Insight Medbotics